Compare GENB & GAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | GENB | GAM |
|---|---|---|
| Founded | 2018 | 1927 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Investment Managers |
| Sector | | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.5B |
| IPO Year | N/A | N/A |
| Metric | GENB | GAM |
|---|---|---|
| Price | $17.35 | $63.90 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $23.20 | N/A |
| AVG Volume (30 Days) | ★ 1.1M | 32.0K |
| Earning Date | 05-11-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 5.74% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 11.67 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $16.58 | N/A |
| P/E Ratio | ★ N/A | $5.48 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.00 | $56.24 |
| 52 Week High | $18.18 | $66.18 |
| Indicator | GENB | GAM |
|---|---|---|
| Relative Strength Index (RSI) | 66.93 | 55.45 |
| Support Level | $11.73 | $62.29 |
| Resistance Level | N/A | $64.52 |
| Average True Range (ATR) | 1.22 | 0.85 |
| MACD | 0.29 | 0.09 |
| Stochastic Oscillator | 87.19 | 67.18 |
Generate Biomedicines Inc is a clinical-stage generative biology company pioneering the AI revolution in biotechnology and drug design and development. The company's single operating segment is engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics. Its product candidates include: GB-0895, GB-4362, and GB-5267. Through the company's Generate Platform, it can generate medicines on demand across multiple therapeutic modalities with unprecedented speed representing a fundamental shift in drug discovery.
General American Investors Co Inc is a closed-end, diversified management investment company. The primary investment objective of the company is long-term capital appreciation through investment in companies with above-average growth potential. It focuses on equity securities with growth potential at reasonable valuations. The company invests principally in common stocks believed by management to have growth potential.